Active ingredient
Deferasirox
96 finished FDA listings contain Deferasirox as their only active ingredient.
FDA NDC Directory
- Ingredient names as written by FDA
- DEFERASIROX
- Dosage forms
- Granule, Tablet, Tablet, Film Coated, Tablet, For Suspension
- Routes
- Oral
- Manufacturers / labelers
- 22
- Strengths listed
- 125 mg/1 · 180 mg/1 · 250 mg/1 · 360 mg/1 · 500 mg/1 · 90 mg/1
- Brand names in FDA listings
- Deferasirox Oral Granules, Deferasorox, Exjade, Jadenu
RxNorm (National Library of Medicine)
Ingredient concept RxCUI 614373
Drugs@FDA applications
Linked only where the FDA listing’s application number matches Drugs@FDA exactly. A listing in the NDC Directory does not by itself mean FDA approval.
| Application | Sponsor | Original approval | Listings |
|---|---|---|---|
| NDA 021882 | NOVARTIS | 2005-11-02 | 3 |
| NDA 206910 | NOVARTIS PHARMS CORP | 2015-03-30 | 3 |
| ANDA 203560 | ACTAVIS ELIZABETH | 2016-01-26 | 2 |
| NDA 207968 | NOVARTIS | 2017-05-18 | 3 |
| ANDA 210060 | ALEMBIC | 2019-11-20 | 6 |
| ANDA 210519 | ALKEM LABS LTD | 2019-11-20 | 3 |
| ANDA 210920 | BIONPHARMA | 2019-11-20 | 3 |
| ANDA 209878 | MSN | 2019-11-20 | 9 |
| ANDA 210945 | MSN | 2019-11-20 | 7 |
| ANDA 211383 | ZYDUS PHARMS | 2019-11-20 | 6 |
| ANDA 211824 | ALEMBIC | 2019-11-20 | 6 |
| ANDA 209782 | SUN PHARM | 2019-11-20 | 3 |
| ANDA 210727 | STEVENS J | 2019-12-27 | 3 |
| ANDA 212995 | PIRAMAL | 2019-12-30 | 3 |
| ANDA 209433 | GLENMARK SPECLT | 2020-01-03 | 3 |
| ANDA 210555 | ALKEM LABS LTD | 2020-03-30 | 3 |
| ANDA 213374 | ALKEM LABS LTD | 2020-07-14 | 3 |
| ANDA 214559 | AUCTA | 2021-03-09 | 3 |
| ANDA 214650 | MSN | 2021-03-17 | 3 |
| ANDA 214341 | ANNORA PHARMA | 2021-05-14 | 3 |
| ANDA 215026 | CIPLA | 2022-02-23 | 3 |
| ANDA 216229 | ANNORA PHARMA | 2022-09-22 | 3 |
| ANDA 207124 | TEVA PHARMS USA | 2022-09-23 | 3 |
| ANDA 214474 | AUROBINDO PHARMA LTD | 2023-10-16 | 6 |
| ANDA 215137 | AUROBINDO PHARMA | 2025-09-08 | 3 |
Official labeling on DailyMed
- DEFERASIROX TABLET, FOR SUSPENSION [TEVA PHARMACEUTICALS, INC.] · version 8 · 2026-08-17
- DEFERASIROX ORAL GRANULE [ASCEND LABORATORIES, LLC] · version 9 · 2026-06-19
- EXJADE (DEFERASIROX) TABLET, FOR SUSPENSION [NOVARTIS PHARMACEUTICALS CORPORATION] · version 49 · 2026-01-30
- DEFERASIROX TABLET, FOR SUSPENSION [NOVADOZ PHARMACEUTICALS LLC] · version 1 · 2026-01-30
- DEFERASIROX TABLET [AVKARE] · version 1 · 2026-01-16
- JADENU (DEFERASIROX) TABLET, FILM COATED JADENU (DEFERASIROX) GRANULE [NOVARTIS PHARMACEUTICALS CORPORATION] · version 26 · 2025-12-12
- DEFERASIROX TABLET, FOR SUSPENSION [ACTAVIS PHARMA, INC.] · version 29 · 2025-11-17
- DEFERASIROX GRANULE [AUROBINDO PHARMA LIMITED] · version 1 · 2025-09-15
- DEFERASIROX TABLET, FOR SUSPENSION [ASCEND LABORATORIES, LLC] · version 17 · 2025-07-14
- DEFERASIROX TABLET, FILM COATED [ASCEND LABORATORIES, LLC] · version 13 · 2025-06-09
- DEFERASIROX TABLET, FOR SUSPENSION [BIONPHARMA INC.] · version 4 · 2025-03-10
- DEFERASIROX (DEFERASIROX) TABLET, FILM COATED [CAMBER PHARMACEUTICALS, INC.] · version 3 · 2025-02-13
Showing the 12 most recent of 32 labels.
Sources: FDA NDC Directory (2026-09-29), RxNorm, Drugs@FDA, DailyMed. Each source’s facts are shown separately as published.